Hengrui’s Novo Deal Could Reach $2.6 Billion as Third-Quarter Profit Details Remain Absent

Key Facts

Hengrui Pharmaceuticals announced on September 29, 2026, an exclusive licensing agreement with Novo Nordisk for its experimental drug HRS-1596, in a deal that could reach a total value of $2.6 billion. The value includes an upfront payment of $300 million, along with potential sales royalties, according to Hengrui’s statement. But the company did not say in the statement that the deal boosted third-quarter profits, and the open source does not establish that milestone payments or royalties were received during the quarter. Therefore, based on the available information, the profit growth cited in the previous draft cannot be linked to the licensing agreement. The deal places an experimental drug program in an international partnership, while its maximum value remains contingent on development, regulatory and commercial milestones.

Under the agreement, Novo will receive exclusive rights to develop, manufacture and commercialize HRS-1596 globally, excluding mainland China, Hong Kong, Macau and Taiwan, according to Hengrui’s statement. This arrangement limits the rights transferred to Novo to the markets specified in the agreement, leaving those regions outside its scope. The $2.6 billion is a potential maximum value, not an amount fully payable upon signing. It includes $300 million upfront, while the remainder comprises potential sales royalties and amounts tied to agreement milestones. The open statement did not specify how much might be paid at each milestone or when any of those payments might be triggered.

Hengrui said HRS-1596 is a dual agonist of GLP-1 and GIP receptors and is ready to begin Phase 1 clinical development. It added that it had received approval in China to begin Phase 1 trials of the drug for weight management and Type 2 diabetes. The approval places the program at the start of clinical testing, while future payments under the agreement remain tied to development, regulatory and commercial milestones. The combination of the drug’s early stage and the deal’s potential value means that most of the announced value depends on the program advancing through those stages. The open statement included no clinical trial results or specific timing for the drug to move to a later stage.

Data for the first half of 2026 provides context on Hengrui’s portfolio, but does not by itself explain the third-quarter result. By the end of the reporting period, the company had 17 clinical programs that had reached Phase 3 and 22 programs in Phase 2, while 10 innovative assets had entered Phase 1, according to its disclosure. These figures point to a broad development pipeline across different clinical stages, but provide no details on revenue from each program or its contribution to earnings. Among those assets, HRS-1596 is a program that the company said had received approval to begin Phase 1 in China. The open disclosure does not specify whether the drug was among the 10 assets listed in the first-half data.

In the first half of 2026, Hengrui’s innovative drug sales rose 16.38% year on year and accounted for 63.16% of total drug sales, the company said. Sales of innovative non-oncology drugs also increased 73.97% from the same period a year earlier. These indicators provide a picture of the composition and direction of sales in the first half, but do not establish that the licensing deal or its potential revenue drove third-quarter profit growth. The available facts included no numerical comparison of third-quarter net profit with the year-earlier period or market estimates. The first-half figures therefore provide context for pharmaceutical business performance, not a substitute for details of quarterly results.

Alongside sales and pipeline expansion, Hengrui said its research and development investment totaled 4.61 billion yuan in the first half of 2026, equivalent to 29.8% of revenue. It also said it received 7 innovation-related approvals during the period, including two for first-class innovative drugs. These figures add context on the company’s spending and regulatory activity, alongside the clinical programs it reported at the end of the first half. But they do not specify how much of that spending or those approvals was reflected in third-quarter profits. The available information includes no later announced timeline for HRS-1596 results; Hengrui’s disclosures are limited to the drug’s readiness to begin Phase 1 and China’s approval to launch its trials.